Benchmark Raises PT On Bio-Reference Labs To $29
The Benchmark Company has raised the price target on Bio-Reference Labs (NASDAQ: BRLI) from $25 to $29 and maintains its Buy rating.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Benchmark Bio-Reference LaboratoriesPrice Target Analyst Ratings

